• 1
    Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975; 72: 29948.
  • 2
    Bhagwat SS, Hamann PR, Still WC, Bunting S, Fitzpatrick FA. Synthesis and structure of the platelet aggregation factor thromboxane A2. Nature 1985; 315: 5113.
  • 3
    Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 120618.
  • 4
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 2002; 324: 7186.
  • 5
    Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 1958.
  • 6
    Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 15939.
  • 7
    Roberts LJ, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem 1981; 256: 838493.
  • 8
    Ciabattoni G, Maclouf J, Catella F, FitzGerald GA, Patrono C. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta 1987; 918: 2937.
  • 9
    Karon BS, Wockenfus A, Scott R, Hartman SJ, McConnell JP, Santrach PJ, Jaffe AS. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. Clin Chem 2008; 54: 10605.
  • 10
    Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 16505.
  • 11
    Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KAA, Topol EJ. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid. determinants and effect on cardiovascular risk. Circulation 2008; 118: 1690.
  • 12
    Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, McNicholas KW, Segal JB, Rade JJ. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol 2011; 57: 106977.
  • 13
    Geske FJ, Guyer KE, Ens G. AspirinWorks: a new immunologic diagnostic test for monitoring aspirin effect. Mol Diagn Ther 2008; 12: 514.
  • 14
    Gluckman TJ, Segal JB, Schulman SP, Shapiro EP, Kickler TS, Prechel MM, Conte JV, Walenga JM, Shafique I, Rade JJ. Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. J Thromb Haemost 2009;7:145764.
  • 15
    McLean RC, Nazarian SM, Gluckman TJ, Schulman SP, Thiemann DR, Shapiro EP, Conte JV, Thompson JB, Shafique I, McNicholas KW, Villines TC, Laws KM, Rade JJ. Relative importance of patient, procedural and anatomic risk factors for early vein graft thrombosis after coronary artery bypass graft surgery. J Cardiovasc Surg (Torino) 2011; 52: 87785.
  • 16
    Nazarian SM, Thompson JB, Gluckman TJ, Laws K, Jani JT, Kickler TS, Rade JJ. Clinical and laboratory factors associated with shear-dependent platelet hyper-reactivity in patients on chronic aspirin therapy. Thromb Res 2009; 126: 37983.
  • 17
    Pickett WC, Murphy RC. Enzymatic preparation of carboxyl oxygen-18 labeled prostaglandin F2 alpha and utility for quantitative mass spectrometry. Anal Biochem 1981; 111: 11521.
  • 18
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 30710.
  • 19
    Cayman Chemical. Product Information:11-dehydro Thromboxane B2 EIA Antiserum. [419502]. 10-15-2010.
  • 20
    Caymen Chemical. Product Information:11-dehydro Thromboxane B2 Monoclonal Antibody. [419512]. 2-7-2012.
  • 21
    Paz MA, Lupon J, Bosch X, Pomar JL, Sanz G. Predictors of early saphenous vein aortocoronary bypass graft occlusion. The GESIC Study Group. Ann Thorac Surg 1993; 56: 11016.
  • 22
    Shah PJ, Gordon I, Fuller J, Seevanayagam S, Rosalion A, Tatoulis J, Raman JS, Buxton BF. Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999. J Thorac Cardiovasc Surg 2003; 126: 19727.
  • 23
    Chiabrando C, Rivoltella L, Alberti E, Bonollo M, Djurup R, Fanelli R. Urinary excretion and origin of 11-dehydro-2,3-dinor-thromboxane B2 in man. Prostaglandins 1993; 45: 40111.
  • 24
    Diczfalusy U. Beta-oxidation of eicosanoids. Prog Lipid Res 1994; 33: 40328.
  • 25
    Benigni A, Chiabrando C, Perico N, Fanelli R, Patrono C, FitzGerald GA, Remuzzi G. Renal metabolism and urinary excretion of thromboxane B2 in the rat. Am J Physiol 1989; 257: F7785.
  • 26
    Remuzzi G, FitzGerald GA, Patrono C. Thromboxane synthesis and action within the kidney. Kidney Int 1992; 41: 148393.
  • 27
    Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987; 47: 64756.
  • 28
    Lawson JA, Patrono C, Ciabattoni G, FitzGerald GA. Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. Anal Biochem 1986; 155: 198205.
  • 29
    Catella F, Healy D, Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A 1986; 83: 58615.